Suppr超能文献

脑肿瘤的预后。

Prognostication in brain tumors.

机构信息

Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Neuro-Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

出版信息

Handb Clin Neurol. 2022;190:149-161. doi: 10.1016/B978-0-323-85029-2.00001-4.

Abstract

Despite the use of aggressive multimodality therapies, the prognosis of brain tumor patients remains poor. Tumors of glial origin typically have the worst prognosis, with a predicted median survival of 12-15months for glioblastoma multiforme (WHO grade IV) and 2-5years for anaplastic glioma (WHO grade III). Palliative care problems and needs in patients with primary and secondary brain tumors are significantly different, both due to different trajectory of disease and to variable prognosis which in metastatic brain tumors is related to the natural history of primary tumors. This chapter describes the complex interactions influencing communication and the treatment decision process in primary brain tumor patients. The whole trajectory of disease and particularly the end-of-life (EOL) phase of brain tumor (BT) patients are quite different in respect to the expected trajectory observed in the general cancer population. The need to improve the communication of prognosis in BT patients has been clearly reported in neuro-oncological literature, but several issues may hinder a good communication in these patients. Adequate prognostic awareness (PA) is important for several reasons: to respect patient autonomy, to obtain her/his preferences about treatments and goal of care, and to share EOL treatment decisions. The high incidence of cognitive deficits in BT patients is one of the most challenging issues influencing the quality of communication and the participation of patients in the process of treatment decisions. Impaired neurocognitive functions may impact capacities of understanding, appreciation, reasoning, and expression of choice, reducing Medical Decisions Capacity (MDC). The lack of capacity to express preferences about EOL treatment decisions represents an important ethical issue, with a great impact on both the patient's family and healthcare professionals involved in the decision processes. Also, patients' coping styles may have an important influence in critical aspects of care such as communication of diagnosis and prognosis, discussion with patients and their caregivers about goal of treatments, early introduction of PC, and advanced planning of patients' preferences concerning EOL treatment and issues. Several barriers hinder good communication in BT patients. This chapter analyzes emerging literature data and possible strategies to improve communication about prognosis and goals of care and to promote patients' involvement in the treatment decision process particularly in the palliative care setting.

摘要

尽管采用了积极的多模式治疗,但脑肿瘤患者的预后仍然很差。源自神经胶质的肿瘤通常预后最差,多形性胶质母细胞瘤(WHO 分级 IV)的中位预测生存期为 12-15 个月,间变性神经胶质瘤(WHO 分级 III)为 2-5 年。原发性和继发性脑肿瘤患者的姑息治疗问题和需求有显著差异,这既是由于疾病轨迹不同,也是由于预后不同,而转移性脑肿瘤的预后与原发性肿瘤的自然史有关。本章描述了影响原发性脑肿瘤患者沟通和治疗决策过程的复杂相互作用。与一般癌症患者观察到的预期轨迹相比,脑肿瘤(BT)患者的整个疾病轨迹,特别是终末期(EOL)阶段,有很大的不同。在神经肿瘤学文献中,已经明确报道了需要提高 BT 患者的预后沟通,但在这些患者中,有几个问题可能会阻碍良好的沟通。充分的预后意识(PA)很重要,原因有几个:尊重患者自主权,了解她/他对治疗和护理目标的偏好,并共同做出 EOL 治疗决策。BT 患者认知功能障碍的高发生率是影响沟通质量和患者参与治疗决策过程的最具挑战性问题之一。受损的神经认知功能可能会影响理解、欣赏、推理和表达选择的能力,从而降低医疗决策能力(MDC)。缺乏表达 EOL 治疗决策偏好的能力是一个重要的伦理问题,对患者的家庭和参与决策过程的医疗保健专业人员都有很大的影响。此外,患者的应对方式可能会对护理的关键方面产生重要影响,例如诊断和预后的沟通、与患者及其护理人员讨论治疗目标、早期引入姑息治疗以及提前规划患者对 EOL 治疗和问题的偏好。有几个障碍阻碍了 BT 患者的良好沟通。本章分析了新兴的文献数据和可能的策略,以改善预后和护理目标的沟通,并促进患者参与治疗决策过程,特别是在姑息治疗环境中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验